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MT201 is a fully human monoclonal IgG1 antibody with moderate affinity for epithelial cell adhesion molecule (Ep-CAM) being
clinically developed for the treatment of carcinomas. Like many other clinically validated IgG1 monoclonal antibodies, MT201
primarily acts by antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC). Here, we
analysed ADCC and CDC induced by MT201 and, as reference, trastuzumab against a panel of nine human breast cancer cell lines
expressing distinct surface levels of Ep-CAM and human epithelial growth factor receptor type 2 antigen. Maximal cell lysis by ADCC
by MT201 and trastuzumab in the presence of peripheral mononuclear cells did not significantly differ when averaged over the nine
cell lines, but showed marked differences with respect to individual cell lines. The extent of cell lysis at intermediate surface target
density was highly variable, suggesting a dominant influence of other susceptibility factors. Only one breast cancer cell line was
eliminated via CDC, but only by MT201. Resistance to CDC appeared to correlate with high expression levels of complement
resistance factors. Our present data as well as recent data on the prevalence and prognostic relevance of Ep-CAM expression in
metastatic breast cancer suggest that Ep-CAM-specific monoclonal IgG1 antibodies may have a significant therapeutic potential in the
treatment of breast cancer.
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Over the past few decades, a considerable effort has been devoted
to the discovery and development of novel chemotherapeutics for
the treatment of breast cancer (Burstein et al, 2001; Cristofanilli
and Hortobagyi, 2001). However, although the initial responses to
chemotherapeutic regimens are frequently positive, their duration
is often brief and the majority of patients die shortly after
relapsing. In the US alone, on average approximately 40000
women die from the disease every year (Winer et al, 2001; Weir
et al, 2003). Commonly, the cause for chemotherapy failure is the
emergence and subsequent expansion of drug-resistant tumour
cells. This shortfall in long-term efficacy has led to the quest for
novel forms of therapy that act by a different mode of action. The
last decade has seen the successful development of novel
immunoglobulin (Ig)-based therapeutics, either in the form of
native monoclonal antibodies (mAbs) or as conjugates with
radionuclides and toxins (Clynes et al, 2000; Carter, 2001; White
et al, 2001; Wels et al, 2003; Wiercioch et al, 2003). Unlike
chemotherapeutics, Ig-based therapies can be designed to target
specifically tumour cells via the recognition of antigens over-
expressed on their surface. Mechanisms of mAb-based therapies
can range from antiproliferation and apoptosis by the blockade of
receptor/ligand interactions, the targeted delivery of prodrugs,
toxins, radioisotopes and chemotherapeutics to the engagement of
immune effector mechanisms such as complement-dependent
cytotoxicity (CDC) and antigen-dependent cellular cytotoxicity
(ADCC). Recently, several mAbs that predominantly act by ADCC
and CDC have been approved for the treatment of cancer patients.
These include chimaeric IgG1 mAb rituximab (Rituxan
s) binding
to the B-cell differentiation antigen CD20 for the treatment of B-
cell lymphomas (Grillo-Lopez et al, 1999; Smith, 2003), humanised
IgG1 mAb trastuzumab (Herceptin
s) targeting HER-2 (human
epithelial growth factor receptor type 2) overexpressed in a
subgroup of breast cancers (Vogel et al, 2001), humanised IgG1
alemtuzumab (Campath
s) targeting the differentiation antigen
CD52 for the treatment of B-cell chronic lymphocytic leukaemia
(Hale et al, 1998; Kottaridis et al, 2000; Faulkner et al, 2004) and
edrecolomab (Panorex
s), a murine IgG2a mAb targeting Ep-CAM
(epithelial cell adhesion molecule), which gained temporary
approval in Germany for the treatment of colorectal carcinoma
(Riethmuller et al, 1994; Gruber et al, 1996; Schwartzberg, 2001;
White et al, 2001). Several other mAbs are currently at advanced
stages of clinical development.
Epithelial cell adhesion molecule (also referred to as 17-1A, KSA,
GA733-2 or ESA) is a 40kDa transmembrane glycoprotein that is
expressed at relatively low levels on basolateral cell surfaces of
most human simple epithelia (Balzar et al, 1999). Expression of
Ep-CAM is highest during embryogenesis and in association with
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smetaplastic or neoplastic changes, and lowest in mature epithelial
tissues. Ep-CAM overexpressing cells tend to segregate from
normal cells correlating with the development of a proliferative
and malignant phenotype (Winter et al, 2003). Epithelial cell
adhesion molecule is overexpressed on the majority of human
carcinomas, and frequently expressed de novo on squamous cell
carcinoma of head and neck, bladder and lung (Litvinov et al,
1996; Balzar et al, 1999; Went et al, 2004). For example, a very
recent study determined by quantitative polymerase chain reaction
a 4400-fold overexpression of Ep-CAM in ovarian cancer tissue
relative to normal ovarian epithelium (Kim et al, 2003).
Another antibody target overexpressed on various carcinomas is
the HER-2 (also called ErB2), a 185kDa transmembrane cell
surface glycoprotein and member of the protein tyrosine kinase
receptor family (Schechter et al, 1984; Yamamoto et al, 1986).
Although no ligand for HER-2 was found to date, the molecule has
been shown to heterodimerise with other HER family members,
contributing to the comodulation of their activity in the regulation
of cell growth, differentiation and survival. Overexpression of
HER-2 is thought to play a role in the aberrant proliferation of
cancer cells (Kallioniemi et al, 1991; Rilke et al, 1991).
In a retrospective study of 205 lymph node-positive breast
cancer patients, Gastl and co-workers (Spizzo et al, 2002)
compared the prognostic impact of HER-2 and Ep-CAM over-
expression on patient survival. A highly significant negative
correlation was found between the expression level of Ep-CAM
and disease-free and overall survival. Even patients expressing Ep-
CAM at lower level and not on every tumour cell showed a survival
disadvantage compared to patients with Ep-CAM-negative tu-
mours. High-level Ep-CAM overexpression was detected with
35.6% of patients, while expression of HER-2 was found elevated in
19.5% of the patients, with overexpression of both targets in 13.2%.
Hence, approximately 20% of breast cancer patients overexpressed
Ep-CAM but not HER-2. Only 10% of breast cancer patients had
Ep-CAM-negative tumours. These studies indicated that therapies
targeting HER-2 or Ep-CAM overexpressing tumours, which may
be more aggressive and evasive, are likely to exert a significant
impact on overall survival of breast cancer patients.
The monoclonal IgG1 antibody trastuzumab targeting HER-2
has been approved as monotherapy and in combination with
docetaxel (Taxotere
s) for the treatment of patients with metastatic
breast cancer (Dieras et al, 2001; Leyland-Jones, 2001; Slamon and
Pegram, 2001). Trastuzumab is believed to mediate killing of HER-
2 overexpressing tumour cells via ADCC, CDC as well as
interference with HER-2 signalling (Sliwkowski et al, 1999).
However, as only approximately 15% of breast cancer patients
highly overexpress HER-2, and thus benefit from trastuzumab
treatment (Spizzo et al, 2002), the majority of breast cancer
patients are still in need of IgG1 antibody-based therapies targeting
other more widespread antigens.
MT201 is a fully human IgG1 mAb that binds Ep-CAM with
moderate affinity (Naundorf et al, 2002). A moderate affinity was
chosen in view of toxicity issues with two high-affinity anti-Ep-
CAM mAbs (Khor et al, 1997; LoBuglio et al, 1997; Saleh et al,
1997; de Bono et al, 2002), and an otherwise very benign safety
profile of the moderate affinity murine IgG2a mAb edrecolomab
(Panorex
s) (Braun et al, 1999; Kirchner et al, 2002; Punt et al,
2002). Preclinical studies have shown that MT201 mediates target
cell lysis via ADCC and CDC in various human cancer cell lines
(Naundorf et al, 2002). Efficacy was also shown in vivo in nude
mouse xenograft models using the Ep-CAM-positive human colon
cancer cell line HT-29 (Naundorf et al, 2002), and ex vivo using
primary human ovarian tumour samples (Xiang et al, 2003).
Here, we report on in vitro studies evaluating the ADCC- and
CDC-mediated cytotoxic efficacy of MT201 against a panel of nine
human breast carcinoma cell lines. In all experiments, efficacy of
MT201 was compared to that of trastuzumab as a reference.
Surface expression of both Ep-CAM and HER-2 was determined
for all cell lines, and mAb-mediated cytotoxicity analysed in
relationship to target density and complement resistance factor
expression. At concentrations corresponding to targeted serum
trough levels, MT201 appeared equally active in ADCC as
trastuzumab, suggesting that clinical administration of MT201
could also provide benefit to breast cancer patients. Given the
more frequent overexpression of Ep-CAM on metastatic breast
cancer than HER-2, MT201 may have a comparable if not higher
therapeutic potential than HER-2-specific antibodies.
MATERIALS AND METHODS
Cell lines and reagents
The KATO III human gastric carcinoma cell line was obtained
from the European Collection of Cell Cultures (ECACC, Salisbury,
UK). The various breast cancer cell lines were obtained from either
the German Collection of Microorganisms and Cell Cultures
(DSMZ, Braunschweig, Germany) or from the American Type
Culture Collections (ATCC, Manassas, VA, USA). Cells were
cultured in RPMI media (Invitrogen, Karlsruhe, Germany),
supplemented with 10% foetal bovine serum (Invitrogen, Karls-
ruhe, Germany), at 371C, in a 5% CO2 chamber. Human sera for
CDC assays were obtained from healthy donors and immediately
stored at 201C after centrifugation of coagulated peripheral
blood. The variable domains of MT201 were isolated from a human
IgD-positive B-cell repertoire by guided selection and phage
display and combined with human IgG1 constant domains as
described previously (Raum et al, 2001). MT201 was produced by
Chinese hamster ovary (CHO) cells and purified to homogeneity
by standard procedures. Trastuzumab (anti-HER-2, Herceptin
s)
mAb was obtained from Hoffmann La-Roche (Grenzach-Whylen,
Germany). The mouse anti-Ep-CAM IgG2a mAb M79 was a kind
gift from Drs Peter Kufer and Judy Johnson (Institute for
Immunology, Ludwig-Maximilians University Munich, Germany)
(Gottlinger et al, 1986). The mouse anti-HER-2 IgG1 mAb 9G6 was
obtained from BD Biosciences (Heidelberg, Germany). The murine
IgG1 anti-CD55 mAb was purchased from the International Blood
Group Reference Laboratory (IBGRL, Bristol, UK)and the murine
IgG2b anti-CD59 mAb from Pharmingen (Heidelberg, Germany).
FITC-conjugated anti-mouse IgG was purchased from DAKO
(Hamburg, Germany), while FITC-conjugated anti-human IgG was
purchased from ICN (Eschwege, Germany).
Saturation binding assay
Saturation binding assays were carried out using the QIFIKIT from
DAKO following the manufacturer’s recommendations (Hamburg,
Germany). All steps were performed on ice. Briefly, cells grown
under regular growth conditions were trypsinised for 5min,
sedimented by centrifugation at room temperature for 5–7min at
200–450g and resuspended to 10
6cellsml
1. A measure of 50ml
of cells (i.e. 510
4) are then added to each well of a 96-well plate,
in duplicate for each experimental condition. After centrifugation
of the culture plates at 350g for 4min, cells were resuspended in
50ml of a three-fold serial dilution of the primary antibody in FACS
(fluorescence-activated cell sorting) buffer as follows: 300, 100,
33.3, 11.1, 3.7, 1.2, 0.4 and 0.13mgml
1 and a blank (FACS buffer
alone), and then incubated at 2–81C for 45min. To quantify target
expression, 100ml of either set-up beads or calibration beads are
pipetted into two separate wells. Cells and the beads were then
sedimented by centrifugation at 300g at 41C for 4min and
washed twice in 200ml of FACS buffer. Cells and calibration beads
are then resuspended in 100ml of the appropriate secondary
antibody (anti-human IgG FITC or anti-mouse IgG FITC).
Following incubation at 2–81C for 45min, samples are washed
three times as above and resuspended in 200ml of FACS buffer.
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sStaining is then analysed by flow cytometry using a FacsCalibur
(BD Biosciences, Heidelberg, Germany) and recording 2500 events.
Determination of surface antigen expression is then determined by
extrapolation from curves derived from the calibration beads.
Dose–response curves were computed by nonlinear regression
analysis using a four-parameter fit model using Prism software
(GraphPad Software, San Diego, CA, USA).
ADCC assays
Target cells grown under regular culture conditions were
trypsinised for 5min, sedimented by centrifugation and resus-
pended in culture medium to a concentration of 10
6 cellsml
1.
Cells (510
6) are then mixed with calcein to a final concentration
of 0.2mM and incubated at 371C for 25min. After one wash with
PBS, cells were resuspended in culture media and adjusted to a
concentration of 310
5 cellsml
1. Separately, peripheral blood
mononuclear cells (PBMC) were prepared following conventional
procedures (enriched by Ficoll–Hypaque gradient centrifugation),
washed and resuspended at 610
6ml
1. Equal volumes of target
and effector cell suspensions are mixed resulting in a final ratio of
effector to target cells (E:T) of 20:1, and 100ml of this cell mixture
is then added per well of a 96-well plate. This is followed by the
addition of 20ml of an antibody solution, previously diluted in a
1:4 series, resulting in a final concentration ranging from 0.2 to
50000ngml
1. Cells are then incubated for 3.5h at 371C, after
which 50ml of propidium iodide (PI) solution is added to yield a
final concentration of 1mgml
1. The cells are further incubated for
another 30min at 371C and 20000 cells are then analysed by Flow
Cytometry using a FacsCalibur (BD Biosciences, Heidelberg,
Germany). Dose–response curves were computed by nonlinear
regression analysis using a four-parameter fit model using Prism
software (GraphPad Software, San Diego, CA, USA). All experi-
ments were performed in triplicate.
CDC assays
Target cells grown under regular culture conditions were
trypsinised for 5min and resuspended in RPMI media at a
concentration of 510
6 cells per 1.7ml of media. Calcein was
added to a final concentration of 10mM and the cells incubated for
30min at 371C. Cells were then washed twice in PBS and
resuspended in prewarmed RPMI media (371C) to a final
concentration of 0.62510
5 cellsml
1. To each 160ml of cell
suspension, 20ml of cold human serum and 20ml of a 1:2 serial
dilution of MT201 were added. In all, 10 concentrations of MT201
ranging from 95 to 50000ngml
1 final, plus a blank control, were
used. After incubation of the cell cultures for 45min at 251C, cells
were sedimented and 100ml of the supernatant analysed by
fluorometry to measure cell death (calcein release) at 485/535nm
using SPECTRAFluor Plus reader (BD Biosciences, Heidelberg,
Germany). Total lysis of the cells was achieved by solubilising a
non-MT201-treated control sample with 20ml of a 9% solution of
Triton X-100. Specific lysis was then determined as the percentage
of the measured calcein release from MT201-treated and the Triton
X-100-solubilised sample. Data analyses were carried out using
Excel (Microsoft, Munich, Germany) and Prism software (Graph-
Pad Software, San Diego, CA, USA). All experiments were
performed in triplicate.
RESULTS
Ep-CAM and HER-2 surface expression on nine breast
cancer cell lines
We quantitated the surface target density of Ep-CAM and HER-2
on nine breast cancer cell lines, which were of different tumour
source and differed with respect to the status of oestrogen receptor
expression, HER-2 amplification and expression of FGF and TGFa
(Table 1). Saturation binding assays were performed under
conditions that prevent downmodulation of antigens by antibody
binding. The technique used microbeads coated with predeter-
mined concentrations of antibody as calibration standards and
required murine antibodies. Murine anti-Ep-CAM mAb M79
(Gottlinger et al, 1986) and anti-HER-2 mAb 9G6 (van de Vijver
et al, 1988) were selected because they had binding affinities
similar to MT201 and trastuzumab, respectively. A 5-min trypsin
treatment used for detachment of cells from culture dishes did not
result in loss of surface antigen density when compared to EDTA
treatment (data not shown).
The Ep-CAM surface density on the nine breast cancer cell lines
ranged from 6.7110
5 binding sites/cell on MT-3 cells to just
1.710
3 on MDA-MB-231 cells (Table 2). Analysis of human Ep-
CAM-negative CHO cells revealed background binding in the
order of 10
3 sites/cell (data not shown), indicating that the MDA-
MB-231 cell line can be considered as Ep-CAM negative. Except for
the latter, the remaining eight cell lines all expressed more than 10
5
sites/cell, and in three of the cell lines (MT-3, ZR-751 and MCF7),
expression levels exceeded 210
5 molecules. HER-2 expression
also varied over a broad range from 9.7610
5 on SKBR3 to just
1.410
4 on MDA-MB-231 cells. However, the relative expression
levels of HER-2 were not as evenly distributed as for Ep-CAM.
Although two cell lines expressed HER-2 above 210
5 (the other
Table 1 Properties of human breast carcinoma cell lines
Primary tumour Origin Comment
MT-3 Breast carcinoma Mammary gland Passaged in nude
mice
SKBR3 Breast
adenocarcinoma
Pleural effusion HER-2
overamplification
MCF7 Breast
adenocarcinoma
Pleural effusion Oestrogen
receptor positive
MaTu Breast carcinoma Mammary gland Passaged in nude
mice
ZR-7513 Breast ductal
carcinoma
Ascites Oestrogen
receptor positive
BT20 Breast carcinoma Mammary gland HER-2
overamplification
MDA-MB-453 Breast carcinoma Pleural effusion FGF expression
MDA-MB-231 Breast carcinoma Mammary gland TGFa expression
BT474 Breast ductal
carcinoma
Mammary gland HER-2
overamplification
Table 2 Expression of Ep-CAM and HER-2 on human breast carcinoma
cell lines
Cell line
Ep-CAM
expression
a
HER-2
expression
a
Ep-CAM:
HER-2 ratio
MT-3 671.2 (7123.1) 27.4 (72.7) 24:1
ZR-751 298.2 (798.2) 68.9 (73.8) 4:1
MCF7 222.1 (713.7) 25.2 (71.6) 9:1
MDA-MB-453 180.3 (730.7) 160.7 (773.5) 1:1
BT20 139.5 (727.0) 41.1 (76.1) 3:1
SKBR3 125.5 (731.6) 976.2 (7292.8) 1:8
MaTu 123.9 (734.2) 16.7 (70.7) 7:1
BT474 122.0 (740.0) 690.6 (7247.0) 1:6
MDA-MB-231 1.7 (70.6) 14.1 (71.5) 1:8
KATO III 893.1 (7166.7) 23.4 (74.0) 38:1
aNumber of binding sites (10
3). Saturation titration analysis was carried out as
described in Materials and Methods. KATO III cells served as reference cell line. The
mean numbers of binding sites from three different experiments and standard
deviations are shown.
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scell line being BT474 at 6.9110
5), only one other cell line
expressed HER-2 above 10
5 (MDA-MD-453 at 1.6110
5), while all
other cell lines expressed less than 6.910
4 molecules per cells
(Table 2). The median expression for Ep-CAM on the nine breast
cancer cell lines was 1.4910
5, and for HER-2 was 3.1610
4,
showing a 4.4-fold difference. Ep-CAM and HER-2 expression on
the gastric carcinoma KATO III reference cell line reached
8.9310
5 and 2.310
4 binding sites/cell, respectively.
ADCC by MT201 and trastuzumab against nine breast
cancer cell lines
The effector cell-mediated cytotoxic efficacy of MT201 and
trastuzumab was analysed using the panel of nine different human
breast carcinoma cell lines of various antibody target antigen
densities (Tables 1 and 2). The human gastric carcinoma cell line
KATO III, which has previously been shown to express high levels
of Ep-CAM and to be sensitive to MT201-mediated ADCC and
CDC (Naundorf et al, 2002), served as reference cell line. As source
of effector cells for ADCC, PBMC from healthy donors were used at
an E:T ratio of 20:1. Analysis of enriched effector cell
subpopulations showed that natural killer cells typically contrib-
uted 490% of ADCC activity within PBMC (Prang et al,
submitted). The same donor PBMCs were used for direct
comparison of MT201 and trastuzumab with each cell line tested.
Dose–response analyses allowed determining EC50 values as well
as the percentage of maximal cell lysis after a 4-h ADCC reaction
(Figure 1). The proportion of alive and lysed cells was determined
by FACS analysis using the dye PI (Naundorf et al, 2002). An
isotype control IgG1 failed to induce target cell lysis above
background (data not shown). Figure 1 shows representative
examples of ADCC dose–response curves derived from four cell
lines expressing different relative levels of Ep-CAM and HER-2
(see Table 2).
With the cell lines KATO III and MT-3 cells, where Ep-CAM is
more highly expressed than HER-2, MT201 reached higher levels
of cell lysis in the 4-h assay than trastuzumab. With MDA-MB-453
cells, which expressed comparable levels of Ep-CAM and HER-2,
cells were more susceptible to lysis by trastuzumab than MT201.
Finally, with BT474 cells, which expressed approximately seven
times more HER-2 than Ep-CAM, trastuzumab was as active as on
MDA-MB-453 cells, while MT201 showed very little activity. ADCC
values for all cell lines expressed as percent maximal-specific cell
lysis are summarized in Table 3. The range of specific lysis induced
by MT201 varied between a maximum of 44.3% for MDA-MB-453
to a low of 6.2% for the MDA-MB-231 line. These levels were
generally comparable to those achieved by trastuzumab, where the
range varied from a maximum of 64.1% for MDA-MB-453 cells to
7.6% for BT20 cells. The median lysis over nine breast cancer cell
lines was 20.2714.6% for MT201, and 27.9715.0% for trastuzu-
mab, and not significantly different. Trastuzumab was generally
able to yield higher cell lysis at a lower antigen expression level
than MT201 as reflected by lower EC50 values (Table 4). For
MT201, EC50 values varied from 461.4ngml
1 for SKBR3 cells to
11.9ngml
1 for BT474. For Herceptin, they ranged from
138ngml
1 for BT20 cells to 4.4ngml
1 for MDA-MB-453 cells.
BT20 cells yielded high EC50 values for the two antibodies, which
also correlated with the lowest specific maximal lysis observed
(compare Tables 3 and 4).
Overall, the specific cytotoxicity of MT201 and trastuzumab
correlated only to a low degree with the respective target densities
on each cell line (Figure 2). With four cell lines of high target
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Figure 1 Examples of ADCC dose–response analyses with MT201 and trastuzumab. Three human breast cancer cell lines expressing different relative
levels of Ep-CAM and HER-2 were selected. The KATO III cell line served as reference. Increasing concentrations of MT201 (triangles) or trastuzumab
(circles) were tested with human PBMC as effector cells at an E:T ratio of 20:1 for 4h. Specific cytotoxicity refers to the difference in cell lysis seen between
antibody-treated and control cell cultures. Cell lysis was determined by staining target cells with PI and subsequent analysis by FACS.
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sdensity for Ep-CAM and HER-2, maximal cell lysis by MT201 and
trastuzumab was very similar.
CDC by MT201 and trastuzumab on nine breast cancer cell
lines
We next assessed whether MT201 and trastuzumab could induce
breast cancer cell lysis via CDC. Freshly purified human serum
from healthy volunteers was used as source of complement. The
only two cell lines susceptible to CDC by MT201 were MT-3 cells
and the KATO III reference cell line (Table 5). No MT-3 and KATO
III target cell lysis was observed when cells were incubated with an
isotype control antibody, or after heat treatment of the human
serum (data not shown). None of the 10 cell lines tested showed
any CDC by trastuzumab, suggesting that neither CDC nor direct
receptor-mediated mechanisms could substantially contribute to
cell lysis under our experimental conditions.
The response of the various cell lines to MT201-induced CDC
appeared to correlate negatively with the expression of certain
complement resistance factors (Table 5). The best correlation to
CDC resistance was seen with the expression level of CD59. KATO
III cells, which exhibited the greatest sensitivity to CDC, expressed
the lowest level of CD59, while they still expressed resistance
factors CD55 and CD46 to a level comparable to that of the other
cell lines. Of all breast cancer cell lines tested, MT-3 cells was the
only cell line susceptible to CDC. It had the lowest level of CD59
and highest level of Ep-CAM expression.
DISCUSSION
The modes of action of MT201 and trastuzumab should be highly
related. Both antibodies recognise targets that are overexpressed
on tumour cells relative to normal tissue, and overexpression of
both targets was found to correlate negatively with overall patient
survival. Both antibodies share the same human Fcg1 (constant
region of Ig type 1) portion that, among all human Fcg subtypes, is
best suited to mediate ADCC (Trinchieri and Valiante, 1993;
Yokoyama and Plougastel, 2003). Differences between MT201 and
trastuzumab may therefore largely relate to their target binding
affinities and the biology and quality of the recognised antigens.
Ep-CAM has no known signalling functions and to date no
antibody against the molecule has been reported to significantly
affect cell proliferation or survival. In contrast, antibody binding to
HER-2 is thought to induce receptor-mediated intracellular
signalling leading to antiproliferative effects (Chazin et al, 1992).
Table 3 ADCC-mediated target cell lysis by MT201 and trastuzumab
Cell line
No. of
experiments MT201
a Trastuzumab
a
MT201:
trastuzumab
MT-3 3 41.4 (710.5) 31.9 (76.7) 1.3:1
ZR-751 3 13.5 (74.3) 14.5 (74.3) 1:1.1
MCF7 3 23.5 (78.3) 25.3 (711.1) 1:1.1
MDA-MB-453 3 44.3 (77.2) 64.1 (75.9) 1:1.4
BT20 3 6.7 (72.8) 7.6 (70.7) 1:1.1
SKBR3 3 8.3 (74.9) 33.2 (715.1) 1:4
MaTu 3 25.8 (72.4) 19.8 (74.7) 1.3:1
BT474 3 10.8 (75.2) 36.5 (73.8) 1:3.4
MDA-MB-231 3 6.2 (71.7) 17.0 (74.4) 1:2.7
KATO III 7 39.9 (714.1) 20.5 (711.7) 2:1
ADCC (antibody-dependent cellular cytotoxicity) is expressed as specific maximal
cell lysis in percent of all target cells as observed in dose–response analyses (see
Figure 1). The assay used human PBMC effector cells at an E:T ratio of 20:1 in 4-h
assay. KATO III cells served as reference cell line. Specific maximal cell lysis refers to
the percentage of target cell cytotoxicity detected in the presence of antibody above
background spontaneous lysis. The mean values from the indicated number of
experiments and standard deviations are shown.
aSpecific maximal cell lysis (%).
Table 4 ADCC-mediated target cell lysis by MT201 and trastuzumab
Cell line
No. of
experiments MT201
a Trastuzumab
a
MT201:
trastuzumab
MT-3 4 47.7 (728.1) 20.5 (77.2) 2.3:1
ZR-751 3 200.3 (735.1) 15.7 (79.3) 12.8:1
MCF7 3 100.8 (799.9) 11.3 (73.4) 8.9:1
MDA-MB-453 3 92.1 (771.1) 4.4 (71.3) 20.9:1
BT20 3 311.5 (747.7) 138 (7106.7) 2.3:1
SKBR3 3 461.4 (7238.3) 16.1 (79.1) 28.7:1
MaTu 3 262.3 (7249.0) 112.7 (786.6) 2.3:1
BT474 3 11.9 (76.5) 8.3 (73.2) 1.4:1
MDA-MB-231 3 N/A 65.9 (736.5) N/A
KATO III 13 84.6 (757.7) 117.3 (771.1) 1:1.4
Antibody concentrations that triggered half-maximal cell lysis by ADCC (see Figure 1)
are shown. The assay used human PBMC effector cells at an E:T ratio of 20:1 in 4-h
assay. Numbers give mean values from the indicated number of experiments and
standard deviations. KATOIII cells served as reference cell line. N/A: not assessed.
aEC50 values in ngml
1.
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Figure 2 Correlation between target densities of Ep-CAM and HER-2
with ADCC of MT201 and trastuzumab. Expression of Ep-CAM and HER-2
on nine breast cancer cell lines was determined by saturation binding assays
as shown in Table 2. ADCC refers to maximal specific cell lysis as shown in
Table 3.
Table 5 CDC of MT201 and trastuzumab and expression of
complement resistance factors
Cell line
CDC by
MT201
a
CDC by
trastuzumab CD46
b CD55
b CD59
b
MT-3 30–50  ++ ++ +
ZR-751  ++ + + +
MCF7  + +++ ++
MDA-MB-453  +++ + +
BT20  +++ +++ ++
SKBR3  ++ +++ +++
MaTu  ++ +++ +++
BT474  +++
MDA-MB-231  + +++ +++
KATO III 80–100  ++ + 
CDC and the expression of complement resistance factors CD46, CD55 and CD59
was determined on all cell lines as described in Materials and Methods. Antibody
concentrations up to 50mgml
1 were tested. Expression of CD46, CD55 and CD59
was determined by FACS analysis using commercial antibody reagents.
aSpecific cell
lysis (%).
b, no staining; +, weak staining; ++ intermediate staining; +++ strong
staining.
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trastuzumab against a panel of nine different breast cell lines in the
absence of effector cells (data not shown). While we cannot
exclude that incubation times longer than those used in our assays
may be needed in order to detect immune effector-independent
activities of trastuzumab, the only measurable cytotoxic activity
that could be observed for trastuzumab in our study was ADCC. It
might be possible that the somewhat higher ADCC activity of
trastuzumab compared to MT201 was due to sensitisation of target
cells via a receptor-mediated cytotoxic mechanism. Such a
sensitisation did, however, not manifest in the presence of
complement. A simpler explanation for the lower EC50 values of
ADCC of trastuzumab compared to MT201 is that the anti-HER-2
antibody has an approximately 100-fold higher binding affinity
than MT201, leading to higher surface density of bound antibody.
Similarly, higher levels of ADCC were achieved by MT201 over
trastuzumab with cell lines expressing high levels of Ep-CAM and
low levels of HER-2. Hence, the lower target binding affinity of
MT201 may be compensated by a higher expression level and
prevalence of the Ep-CAM over the HER-2 target. Moreover, in this
study, we have selected ADCC assay conditions suitable to identify
fine differences in ADCC activity between trastuzumab and
MT201. In a clinical setting, exposure times of tumour cells to
effector cells and antibody will not be 4h but several weeks. As a
consequence, such differences may diminish and much higher
levels of ADCC might be observed for both antibodies.
An interesting observation was that six breast cancer cell lines
differed only by a factor of two in Ep-CAM expression, namely
between 1.24 and 2.2210
5 sites/cell. Despite a very similar target
density, these six cell lines drastically differed with respect to
ADCC susceptibility, namely between 6.7 and 44.3% specific lysis.
This suggests that at an intermediate Ep-CAM target density other
factors that can impact on susceptibility to cellular cytotoxic may
become dominant. Such factors could include overexpressed
protease inhibitors (serpins) or antiapoptotic proteins involved
in immune evasion (Trowsdale and Parham, 2004). Likewise, the
correlation of ADCC induced by trastuzumab with HER-2
expression levels was not very strong.
The absence of any CDC activity by trastuzumab suggests that
the antibody cannot promote assembly of the entire complement
cascade. Likewise, it is possible that CDC requires a rather high
target antigen density and that a cell line such as SKBR3 with the
highest density for HER-2 (similar to that of Ep-CAM on MT-3
cells) also happened to express high levels of complement
resistance factor CD59, whereas MT-3 cells with a comparably
high Ep-CAM target density happened to express low levels of
CD59. Ep-CAM, which forms a tetramer (Balzar et al, 2001), may
also allow for a closer binding of two IgG1 molecules and can
thereby better mediate C1q assembly and CDC than trastuzumab
binding to HER-2. The contribution of CDC to the cytotoxic
activity of IgG1 in solid tumours may generally be underestimated
when studying cultured cell lines. We have here observed a high
expression level of complement resistance factors CD46, CD55 and
CD59 on almost all cell lines. IHC studies of tumour samples from
various stages of colorectal cancer, however, showed that CD59
and CD55 expression is far less frequent than seen with our
tumour cell lines (Koretz et al, 1993; Hosch et al, 2001). As CD59
can interact with CD2 on T cells, there may even be a selective
pressure against CD59 expression on tumour cells to avoid
interaction with T cells (Hahn et al, 1992; Koretz et al, 1993).
In designing a novel antibody against Ep-CAM, experiences with
other Ep-CAM antibodies and IgG1 mAb therapies need to be
considered. Unlike the murine antibody edrecolomab (Panorex
s),
which rapidly loses efficacy in man due to neutralisation by anti-
edrecolomab antibodies, a novel anti-Ep-CAM antibody should be
a human IgG1 and of lowest possible immunogenicity. Only these
two features can guarantee maximal serum half-life and efficacy
through optimal compatibility with human immune effector
mechanisms (ADCC and CDC). This goal was achieved with
MT201 by isolating Ep-CAM-specific VH and VL domains from a
human IgD-positive B-cell repertoire essentially free of somatic
mutations (Raum et al, 2001), and their fusion to human IgG1
constant domains. Moreover, from a safety standpoint, an anti-Ep-
CAM antibody must be able to discriminate between the low levels
of Ep-CAM found on normal tissues and the Ep-CAM over-
expressed on malignant tissues. There is evidence from clinical
trials with high-affinity anti-Ep-CAM antibodies, which caused
acute pancreatitis with an increase in serum levels of amylase and
lipase (Better et al, 2002), that Ep-CAM on normal tissue can be
recognised by these antibodies. On the other hand, edrecolomab
with a moderate affinity in the range of MT201 (Naundorf et al,
2002) showed in more than 3000 treated patients a relatively
benign safety profile (Riethmuller et al, 1994; Punt et al, 2002). An
additional therapeutic window for MT201 may come from an
engagement and sequestration of Ep-CAM within homotypic cell
adhesion zones present between normal epithelial cells. Antibody
binding to the few disengaged Ep-CAM molecules on the
basolateral side of normal epithelial cells may not suffice to form
cytolytic synapse with effector cells nor for effective complement
fixation. Moreover, in vitro cell culture reaggregation assays have
shown that high-affinity anti-Ep-CAM antibodies such as 323/A3
can block cell adhesion at concentrations of 10mgml
1 (Litvinov
et al, 1994). Therefore, high-affinity but not intermediate affinity
anti-Ep-CAM mAbs may be able to damage directly the insulating
function of normal (pancreatic) epithelia by neutralising Ep-
CAM’s epithelial cell adhesion function.
In light of the previous experience with anti-Ep-CAM anti-
bodies, we selected a moderate Ep-CAM binding affinity for
development of MT201. This required to compromise on a reduced
ADCC activity at low antibody concentrations. The reduced target
affinity of MT201 may, however, be effectively counter-balanced by
two factors. One is the high-level overexpression of Ep-CAM on
many human carcinomas and the high prevalence of Ep-CAM
overexpression. The other is that IgG1 therapies for cancer
treatment require relatively high serum trough levels, typically in
excess of 10mgml
1, at which concentration target binding is in
saturation even for low-affinity antibodies. High trough levels are
counter-intuitive in light of the relatively high target binding
affinities of most IgG1 mAb therapies. They may relate to the fact
that efficacy is mostly mediated by effector cells bearing the low-
affinity Fcg receptor type III (CD16) (Hazenbos et al, 1996; Clynes
et al, 2000). Therefore, it may be largely the affinity of IgG1 for
CD16 and not for the target antigen that is rate limiting for
efficacy. Furthermore, the quenching of this interaction by extra
IgG in serum will require higher in vivo mAb concentrations for
competition (Naundorf et al, 2002). A key role for CD16 in ADCC
is supported by the observation that a CD16 polymorphism had a
profound impact on the clinical efficacy of rituximab (Cartron et al,
2002). This polymorphism affects the affinity of CD16 for IgG1 by
a single amino-acid difference.
The therapeutic potential of MT201 and trastuzumab in patients
will be affected by several other parameters. Tumour penetration
of antibodies was found to be improved with reduced target
affinity (Weiner and Thakur, 2001), which could be an advantage
for MT201. Likewise, beneficial pharmacokinetic properties such
as long serum half-life and low immunogenicity of MT201 and low
internalisation of the antibody-bound target can positively impact
the efficacy of an antibody in man. The prevalence of Ep-CAM in
metastatic breast cancer and its prognostic relevance (Spizzo et al,
2002) make antibodies against this target very attractive for
patients that are not eligible for trastuzumab treatment. According
to a study by the Gastl group (Gastl et al, 2000; Spizzo et al, 2002),
approximately 25% of patient samples analysed had high levels of
Ep-CAM expression but were HER-2 negative. A total of 90% of all
metastatic breast cancer patients had Ep-CAM-positive tumours,
of which 42% showed high-level and 48% medium to low-level
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sEp-CAM expression. Not only tumours that express high levels of
Ep-CAM molecules on their surface but also certain tumours that
express low to intermediate levels may be susceptible to ADCC by
MT201, as suggested by the data presented in this report (see
Table 3). Treatment with MT201 for several months at high trough
levels may provide ample time for MT201 to recruit immune
effector cells for elimination of tumour cells with a broad spectrum
of Ep-CAM expression levels.
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